Jonathan I Silverberg1, Joel M Gelfand2, David J Margolis2, Luz Fonacier3, Mark Boguniewicz4, Lawrence B Schwartz5, Eric Simpson6, Mitchell H Grayson7, Peck Y Ong8, Zelma C Chiesa Fuxench2. 1. Northwestern University Feinberg School of Medicine, Chicago, Illinois. Electronic address: JonathanISilverberg@gmail.com. 2. University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania. 3. NYU Winthrop Hospital, Mineola, New York. 4. National Jewish Health and University of Colorado School of Medicine, Denver, Colorado. 5. Virginia Commonwealth University School of Medicine, Richmond, Virginia. 6. Oregon Health and Sciences University, Portland, Oregon. 7. Nationwide Children's Hospital, The Ohio State University College of Medicine, Columbus, Ohio. 8. Children's Hospital Los Angeles, University of Southern California, Keck School of Medicine, Los Angeles, California.
Abstract
BACKGROUND: Patient-Oriented Eczema Measure (POEM) is the preferred patient-reported outcome (PRO) for assessing symptoms of atopic dermatitis (AD). Dermatology Life Quality Index (DLQI) is commonly used to assess the burden of skin disease. Previous severity strata were developed for POEM and DLQI in clinical cohorts, which may be biased toward more severe disease. Severity strata were not previously examined in population-based cohorts. Patient-Oriented Scoring AD (PO-SCORAD) is another commonly used PRO for assessing AD symptoms; however, severity strata are not established. OBJECTIVE: We sought to confirm previously developed strata for POEM and DLQI, and to develop strata for the PO-SCORAD in a population-based cohort of adults with AD. METHODS: A cross-sectional, population-based study of 8,217 adults was performed using a structured questionnaire. A diagnosis of AD was determined using modified UK Diagnostic Criteria for AD (n = 602). AD severity was assessed using self-reported global AD severity (anchoring question), POEM, PO-SCORAD, and DLQI. Strata were selected using an anchoring approach based on patient-reported disease severity. RESULTS: We confirmed the existing strata for DLQI (mild = 0-5, moderate = 6-10, severe = 11-30) (kappa = 0.446). However, the preferred strata for POEM was mild = 0-7, moderate = 8-19, and severe = 20-28 (kappa = 0.409) and PO-SCORAD was mild = 1-27, moderate = 28-56, severe = 57-104 (kappa = 0.444). CONCLUSION: Existing strata for DLQI performed well in a population-based cohort of adult AD. The optimal severity strata for the POEM in our AD population varies slightly from those previously published for AD. This may suggest that different strata may be optimal in different study settings and cohorts. Finally, we proposed new strata for PO-SCORAD in adult AD.
BACKGROUND:Patient-Oriented Eczema Measure (POEM) is the preferred patient-reported outcome (PRO) for assessing symptoms of atopic dermatitis (AD). Dermatology Life Quality Index (DLQI) is commonly used to assess the burden of skin disease. Previous severity strata were developed for POEM and DLQI in clinical cohorts, which may be biased toward more severe disease. Severity strata were not previously examined in population-based cohorts. Patient-Oriented Scoring AD (PO-SCORAD) is another commonly used PRO for assessing AD symptoms; however, severity strata are not established. OBJECTIVE: We sought to confirm previously developed strata for POEM and DLQI, and to develop strata for the PO-SCORAD in a population-based cohort of adults with AD. METHODS: A cross-sectional, population-based study of 8,217 adults was performed using a structured questionnaire. A diagnosis of AD was determined using modified UK Diagnostic Criteria for AD (n = 602). AD severity was assessed using self-reported global AD severity (anchoring question), POEM, PO-SCORAD, and DLQI. Strata were selected using an anchoring approach based on patient-reported disease severity. RESULTS: We confirmed the existing strata for DLQI (mild = 0-5, moderate = 6-10, severe = 11-30) (kappa = 0.446). However, the preferred strata for POEM was mild = 0-7, moderate = 8-19, and severe = 20-28 (kappa = 0.409) and PO-SCORAD was mild = 1-27, moderate = 28-56, severe = 57-104 (kappa = 0.444). CONCLUSION: Existing strata for DLQI performed well in a population-based cohort of adult AD. The optimal severity strata for the POEM in our AD population varies slightly from those previously published for AD. This may suggest that different strata may be optimal in different study settings and cohorts. Finally, we proposed new strata for PO-SCORAD in adult AD.
Authors: Sigrídur Lára Gudmundsdóttir; Tommaso Ballarini; María L Ámundadóttir; Judit Mészáros; Jenna H Eysteinsdóttir; Ragna H Thorleifsdóttir; Sigrídur K Hrafnkelsdóttir; Heida B Bragadóttir; Saemundur Oddsson; Jonathan I Silverberg Journal: Dermatol Ther (Heidelb) Date: 2022-10-14
Authors: Jerry Bagel; Tien Q Nguyen; Hermenio Lima; Neal Jain; David M Pariser; Sylvia Hsu; Gil Yosipovitch; Haixin Zhang; Jingdong Chao; Shikha Bansal; Zhen Chen; Daniel Richman; Andrew Korotzer; Marius Ardeleanu Journal: Dermatol Ther (Heidelb) Date: 2022-05-20
Authors: J I Silverberg; D Lei; M Yousaf; S R Janmohamed; P P Vakharia; R Chopra; R Chavda; S Gabriel; K R Patel; V Singam; R Kantor; D Y Hsu Journal: Br J Dermatol Date: 2020-09-21 Impact factor: 9.302
Authors: Trisha Kaundinya; Uros Rakita; Armaan Guraya; Donna Maria Abboud; Emily Croce; Jacob P Thyssen; Andrew Alexis; Jonathan I Silverberg Journal: J Invest Dermatol Date: 2021-08-02 Impact factor: 8.551